Company intelligence / Profile preview

Alfasigma

Bologna and Pomezia, Italyalfasigma.com ↗

Ownership: Private
Employees: ~3000
Development stage: Commercial

Overview

Alfasigma has multiple approved drugs including Ocaliva for primary biliary cholangitis, Filgotinib for ulcerative colitis, Parnaparin Sodium for thrombosis, and several others. The company has expanded its portfolio through acquisitions including Intercept Pharmaceuticals and SOFAR.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularNeurology
Modalities: Small molecule drugsChemical drugsAntibody drug conjugate (ADC)
Industry: Biotech

Drug pipeline

25 assets

obeticholic acid

Approved

24 more assets in the full pipeline.

Request access →

Partnerships

Galapagos (acquired rights to Jyseleca)

Beyond the preview

Go deeper on Alfasigma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfasigma.

Explore the full profile